Azelis proudly presents award-nominated formulation, cutting-edge innovations, and a strengthened portfolio at CPHI Frankfurt 2025

Azelis, the reference innovation service provider in the speciality chemicals and food ingredients industry, will present its latest pharmaceutical innovations at CPHI 2025, taking place from 28 to 30 October at Messe Frankfurt, Germany. At booth 8.0S24, Hall 8, Azelis will display ten advanced formulations developed by its laboratories in the UK, France, Egypt, Türkiye and India, covering liquid, semi-solid and solid formats for both human and veterinary applications. Visitors to the Azelis booth will benefit from:

• First-hand access to ten new, market-ready pharmaceutical formulations addressing evolving patient and consumer needs
• Insights from technical experts on innovation trends, formulation challenges and sustainable solutions
• A closer look at Azelis’s award-nominated Advanced Peristomal Barrier & Adhesion Cream, recognised for excellence in drug delivery and device innovation

The ten formulations presented at the show will cover a wide range of formats, including gummies, syrups, sublingual tablets, topical creams, recovery gels and veterinary films. Each formulation reflects Azelis’s focus on technical excellence and sustainable value creation across the pharmaceutical value chain. Among the formulations presented is the Advanced Peristomal Barrier & Adhesion Cream, selected as a finalist for the CPHI Pharma Awards in the Drug Delivery & Device Innovation category. Developed by our technical Pharma team, the Advanced Peristomal Barrier and Adhesion Cream addresses a long-standing need for improved comfort and protection in ostomy care. This formulation demonstrates Azelis’s commitment to patient-centric innovation, offering enhanced comfort and performance for individuals using medical devices.

Azelis will also showcase its expanded Pharma portfolio, strengthened by the recent acquisitions of ACEF and Solchem. These additions provide customers with broader access to high-quality nutraceutical and pharmaceutical ingredients, supported by Azelis’s global technical expertise and collaborative innovation model.

Evy Hellinckx, CEO Azelis EMEA, comments:

“CPHI Frankfurt is a key event for our industry, and we are proud to be part of it. Our teams have worked passionately to bring forward technical innovations that truly make a difference – not just in pharmaceutical formulation, but in how we collaborate, empower customers and support our partners. Being shortlisted for the second year in a row, and in the CPHI Pharma Awards in the Drug Delivery & Device Innovation category, is a testament to our technical expertise and the value we create together across the pharmaceutical value chain.”

With more than 62,000 attendees, CPHI Frankfurt serves as a key platform for Azelis to engage with customers, principals and partners. Azelis’s presence at CPHI 2025 underlines its role as a trusted innovation partner for the pharmaceutical and nutraceutical industries. 

Azelis’s innovation capabilities are driven by the deep technical expertise of its teams across EMEA, the Americas, and Asia Pacific. The group combines market trends with ingredient expertise and formulation know-how to develop innovative solutions. With this, it inspires and supports its partners in developing new, sustainable products efficiently. Through close collaboration between technical, sales, marketing, and business development specialists, Azelis translates ideas towards ready-to-launch concepts and is dedicated to staying ahead of customer-specific developments, pushing the boundaries of what's possible in innovation to support its customers in their business development journey.